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Introduction
Inflammatory bowel disease (IBD), which includes Crohn’s 
disease and ulcerative colitis (UC), is a debilitating disease 
that affects 1.4 million people in the United States (US) 
(1,2).  The incidence of IBD is strikingly high in North 
America, ranging from 2.2 to 19.2 cases per 100,000 person-
years (3,4). There is a significant heritable component of 
this disease, with first degree relatives having approximately 
a 3–20 times increased likelihood of developing the disease 
(5-9). Environmental causes such as smoking and diets high 
in processed food, refined sugar, and milk protein have been 
theorized as explanations for this increase (10-14).
Additionally, patients with IBD have increased incidence 
of colon cancer and mortality from colon cancer when 
compared to the general population (15,16).   Many 
population-based studies as well as meta-analyses around the 
world have corroborated this finding (17-19). Around the 
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world, the incidence of colon cancer per year is 1.2 million 
and the mortality is 0.6 million per year (20). 
Racial disparities in colon cancer in the general 
population are well established, with African-Americans 
having the highest incidence and mortality and Asians/
Pacific Islanders having the lowest (21). Prior studies 
have analyzed gender and age of patients with IBD who 
develop colon cancer, demonstrating that overall, the risk 
of developing colon cancer is higher for men with IBD 
than for women with IBD and is higher for patients who 
are under the age of 40 (17,22). However, investigation of 
other demographic variables, such as race, in this subset of 
patients remains incomplete. This study seeks to determine 
whether there exists racial disparity in the incidence of 
colon cancer in patients with IBD. Findings from this study 
will help in identifying high risk patients who may develop 
CC and help shape public health efforts to ultimately 
reduce the incidence of colon cancer.
Methods
A retrospective analysis of the 2011 National Inpatient 
Sample (NIS) database was performed. This database is 
maintained by the Agency for Healthcare Research and 
Quality as part of the Healthcare Cost and Utilization 
Project (HCUP). It covers 95% of the US population 
and includes comprehensive abstracted discharged data. 
Inclusion criteria were age >18 years, diagnosis of IBD, and 
diagnosis of colon cancer. Patients were then stratified by 
race (Whites, Blacks, Hispanics, Asians/Pacific Islanders, 
and Native Americans), and gender. Age was also used as a 
variable. These categorical variables were then summarized 
by frequencies and the continuous variables were summarized 
by mean and standard deviation. Log-binomial regression 
was performed to derive relative risk (RR), while adjusting 
for age and gender, and then for IBD. The significance level 
was set at 5%. Our analysis was performed using SAS 9.4. 
For this study, the use of NIS database conformed 
to the data-use agreement from HCUP. This study was 
reviewed by the University of Arizona, Institutional Review 
Board and was determined to be exempt from the need for 
approval.
Results
There was a total of 6,013,105 cases in the database that 
was analyzed in our study, of which 40.5% were male. Of 
these, 70.7% (n=4,250,073) of our total cases were classified 
as White, 15.7% (n=944,957) as Black, 10.9% (n=652,905) 
as Hispanic, 2.2% (n=130,472) as Asian/Pacific Islander, 
and 0.6% (n=34,698) as Native American (Table 1). Of all 
the patients sampled, 1.0% (n=57,542) had a diagnosis of 
IBD, 0.6% (n=33,501) had a diagnosis of colon cancer, and 
0.005% (n=289) had a diagnosis of both. Out of all White 
patients, 1.1% (n=47,014) had a diagnosis of IBD, 0.6% 
(n=24,631) had a diagnosis of colon cancer, and 0.006% 
(n=256) had diagnosis of both. Zero-point-seven percent 
(n=6,668) of Black patients had a diagnosis of IBD, 0.6% 
(n=5,202) had a diagnosis of colon cancer, and 0.002% 
(n=17) had a diagnosis of both. For the Hispanic patients, 
0.5% (n=3,155) had a diagnosis of IBD, 0.4% (n=2,668) 
had a diagnosis of colon cancer, and 0.002% (n=16) had 
a diagnosis of both. Out of all Asian and Pacific Islander 
patients, 0.4% (n=538) had a diagnosis of IBD, 0.7% (n=874) 
had a diagnosis of colon cancer, and 0% had a diagnosis 
of both. Lastly, out of all Native American patients, 0.5% 
Table 1 Results of filtering the data and stratifying by race. Total number of cases with IBD and total number of cases with colon cancer are 
filtered from all the data and percentages are calculated from the total number of individuals in that race. Total number of cases with IBD and CC 
are filtered from cases with IBD and percentages are calculated from total number of individuals with IBD in that race
Race
Total number of all 
cases
Total number of 
cases with IBD (%)
Total number of cases with 
colon cancer (%)
Total number of cases with IBD 
and CC (% for cases with IBD)
White 4,250,073 47,014 (1.1) 24,631 (0.6) 256 (0.006)
Black 944,957 6,668 (0.7) 5,202 (0.6) 17 (0.002)
Hispanic 652,905 3,155 (0.5) 2,668 (0.4) 16 (0.002)
Asian/Pacific Islander 130,472 538 (0.4) 874 (0.7) 0 (0.0)
Native American 34,698 167 (0.5) 126 (0.4) 0 (0.0)
Total 6,013,105 57,542 (1.0) 33,501 (0.6) 289 (0.005)
IBD, inflammatory bowel disease; CC, colon cancer.
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(n=167) had a diagnosis of IBD, 0.4% (n=126) had a 
diagnosis of colon cancer, and 0% had a diagnosis of both. 
For all races, percent of cases that had a diagnosis of both 
IBD and colon cancer were calculated using the patients 
with IBD as the total. 
After adjusting for age, gender, and race in log-binomial 
regression, we found that out of all patients (both with 
and without IBD), increasing age (RR: 1.028, 95% CI: 
1.027–1.028, P<0.0001), Black race (RR: 1.20, 95% CI: 
1.17–1.24, P<0.0001), and Asian race (RR: 1.41, 95% 
CI: 1.32–1.51, P<0.0001) conferred an increased risk for 
developing colon cancer, whereas female gender (RR: 0.76, 
95% CI: 0.75–0.78, P<0.0001), Hispanic race (RR: 0.958, 
95% CI: 0.920–0.997, P=0.04), and Native American race 
(RR: 0.83, 95% CI: 0.69–0.98, P=0.03) conferred a decreased 
risk for developing colon cancer (Table 2). Interestingly, 
patients with IBD had a RR of 1.06 with a 95% CI of 
0.94–1.19, that was not statically significant (P=0.34).
Out of patients with IBD only, increasing age (RR: 1.02, 
95% CI: 1.01–1.03, P<0.0001) was the only statistically 
significant variable that conferred an increased risk of 
developing colon cancer, whereas female gender (RR: 0.56, 
95% CI: 0.44–0.71, P<0.0001) and Black race (RR: 0.59, 
95% CI: 0.36–0.98, P=0.04) conferred a decreased risk for 
developing colon cancer (Table 3). Hispanic race had a RR 
of 1.06 with a 95% CI of 0.64–1.76, that was not statically 
significant (P=0.81). Asian and Native American race were 
not applicable for this analysis since there were no cases 
with IBD and colon cancer in these populations. 
Discussion
Previous studies have shown that the overall incidence of 
colon cancer in patients with IBD is very low (23). This 
finding was confirmed in our study where out of all patients 
with IBD (57,542 patients), only 289 (0.005%) patients 
went on to develop colon cancer (Table 1). Interestingly, our 
study also showed that IBD was not a statistically significant 
risk factor for the development of colon cancer. Previous 
research has been mixed about whether IBD is a statistically 
significant predictor of risk of colon cancer development 
and thus it is not unusual that this variable was not 
significant in our study (24). Some studies have shown that 
IBD does statistically significantly increase the risk of colon 
cancer development, but others have found that it depends 
on which specific type and stage of IBD that is examined 
(24,25). Other studies corroborated our finding that IBD 
does not statistically significantly increase the risk of colon 
cancer and might even decrease the risk (26). This possible 
decrease in risk has been attributed to better screening for 
at-risk populations (26). These conflicting results from the 
various studies could be because UC and Crohn’s disease are 
lumped together and theses might have different impacts 
on carcinogenesis. It will be beneficial in future studies to 
distinguish between Crohn’s disease and UC as well as the 
stage of IBD to better tease out the relationship between 
IBD and the development of colon cancer.  
We demonstrated in our study that advanced age, Black 
race, and Asian race were all statistically significant risk 
Table 3 Relative risk was calculated as before, but in the cohort 
with IBD diagnosis only. Variables were age, gender, race compared 
to Whites, and IBD diagnosis. Age, gender, and Blacks vs. Whites 
achieved significance while Hispanic vs. White did not. There were 
no individuals with both IBD and colon cancer in the Asian and 
Native American groups
Variables RR (95% CI) P value
Age 1.02 (1.01–1.03) <0.0001
Female 0.56 (0.44–0.71) <0.0001
Black race (vs. White) 0.59 (0.36–0.98) 0.04
Hispanic race (vs. White) 1.06 (0.64–1.76) 0.81
Asian race (vs. White) 0 0




IBD, inflammatory bowel disease; RR, relative risk.
Table 2 Using log-binomial regression, relative risk (RR) for colon 
cancer was calculated. Variables were age, gender, race compared to 
Whites, and IBD diagnosis. All comparisons achieved significance 
except for diagnosis of IBD 
Variables RR (95% CI) P value
Age 1.028 (1.027–1.028) <0.0001
Female 0.76 (0.75–0.78) <0.0001
Black race (vs. White) 1.20 (1.17–1.24) <0.0001
Hispanic race (vs. White) 0.958 (0.920–0.997) 0.04
Asian race (vs. White) 1.41 (1.32–1.51) <0.0001
Native American race  
(vs. White)
0.83 (0.69–0.98) 0.03
IBD 1.06 (0.94–1.19) 0.34
IBD, inflammatory bowel disease.
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factors for colon cancer development, while Hispanic race, 
Native American race, and female gender all conferred a 
decreased risk of development of colon cancer (Table 2). 
Our findings on race and gender have been corroborated by 
previous studies (22,23). 
We went on to analyze the incidence of colon cancer 
only in the patients with IBD. Our analysis showed that 
advanced age was still a statistically significant predictor 
of development of colon cancer. Female gender was still 
protective, which corroborates with findings from previous 
studies (17,22). Of the patients with IBD, Hispanics do not 
have a statistically significant increase or decrease in the 
development of colon cancer. However, being Black with 
IBD actually confers a statistically significant less chance 
of developing colon cancer. This is particularly interesting 
because Black race seems to have a protective effect on 
developing colon cancer for the patients with IBD, but an 
increased risk for the general population (both with IBD 
and without). While this finding is perplexing, one possible 
explanation is that Blacks with IBD may follow a more 
prudent surveillance given this population is known to be 
an at-risk group for colon cancer. However, this population 
has also been shown to have less access to healthcare. 
Another possible explanation for this disparity could be due 
to genetic predisposition. Blacks with IBD may possibly 
have a change in their gut flora that may be protective to 
development of colon cancer. Future studies are warranted 
to investigate change in the gut microbiome in patients of 
different races with IBD who develop colon cancer. 
Our study has inherent limitations given that it is a 
retrospective analysis. Our data consisted of a large sample 
size, but the number of patients with IBD and colon cancer 
is small, which could impact the analysis. Another limitation 
is the fact that we could not separate the Crohn’s disease 
patients from the UC patients. This could not be done 
because the database did not separate them and grouped 
both under IBD.
Conclusions
Despite these limitations, our study showed that there are 
racial disparities in the incidence of colon cancer in patients 
with IBD. It also showed that a certain race could be both 
disadvantageous in one setting and protective in another. 
Future studies on larger and more specific databases will 
be useful to fully understand how race and ethnic groups 
impact the likelihood that patients with IBD will develop 
colon cancer. Additional studies on genetic predisposition 
will also help to better understand racial disparities. 
Shedding light on racial disparities will allow for focused 
healthcare efforts for at-risk populations to ultimately 
decrease the incidence and mortality of colon cancer. 
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